--- title: "Takeda Pharmaceutical Co. (4502) stock news and catalysts" url: "https://aibio.space/companies/takeda-pharmaceutical/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "Takeda Pharmaceutical Co. news for investors: Takeda is a Japanese drugmaker that sells medicines for gut and inflammatory diseases, rare diseases…" --- Desk view · Opinion · Updated Oct 22, 2026 ## Takeda bets its rebound on three launches as profit dips Takeda has delivered three new medicines in one year, but they start from a small base while Vyvanse erodes and profit is guided down. Debt and the Amitiza verdict limit flexibility. The launches under new CEO Julie Kim will decide whether the dip is temporary. Read the full desk view aibio.space Investor Rank · Opinion **7** /10 Positive view Three new drugs approved or under priority review, but Vyvanse generics, a guided profit decline, 2.7 times leverage and the Amitiza provision weigh on the position. - **Technology**: 2/2 - **Odds**: 2/2 - **Balance sheet**: 1/2 - **Risk**: 1/2 - **Momentum**: 1/2 Opinion only. The Investor Rank is aibio.space's opinion of the company's business position, drawn from the public sources on this page. It is not a recommendation to buy, sell or hold any security and it is not investment advice. It does not consider the share price, valuation or your circumstances, and it can change at any time. Payments from companies never affect it. [How the rank works](https://aibio.space/disclosures/#rank). - **Technology**: **Three new drugs.** Orzeyful and Mimrylo won FDA approval in August 2026, and zasocitinib beat deucravacitinib head to head in psoriasis. - **Odds**: **Good on regulators, unproven in market.** Zasocitinib is under priority review, and filed drugs win approval 90.6% of the time in BIO's data; launches were 4% of Q1 revenue. - **Balance sheet**: **Profitable but levered.** Net debt was JPY 4,479.0 billion at June 30, 2026, or 2.7 times adjusted EBITDA. - **Main risk**: **Earnings gap and litigation.** Vyvanse generics pull revenue down while the Amitiza verdict led to a JPY 402.5 billion provision. - **Watch next**: **Q2 and Capital Markets Day.** Results come October 29 and the strategy update on December 11, 2026. ## Top news on Takeda ## Dates **October 23, 2026** Late-breaking phase 3 G-HOPE-001 data for arcotatug tavatecan at ESMO [Source](https://www.takeda.com/newsroom/newsreleases/2026/esmo-pipeline-progress/) **October 29, 2026** FY2026 second-quarter results and earnings call [Source](https://www.takeda.com/newsroom/newsreleases/2026/earnings-call-q2-fy2026/) **December 11, 2026** Capital Markets Day in Tokyo [Source](https://www.takeda.com/newsroom/newsreleases/2026/takeda-reports-first-quarter-fy2026-results/) **Second half of calendar 2026** Expected district court judgment in the Amitiza antitrust litigation [Source](https://www.takeda.com/newsroom/newsreleases/2026/financial-results-update-amitiza-antitrust-litigation/) **First quarter of calendar 2027** FDA PDUFA target date for zasocitinib in plaque psoriasis [Source](https://www.takeda.com/newsroom/newsreleases/2026/fda-priority-review-zasocitinib-psoriasis/) ## The money Net debt of JPY 4,479.0 billion at June 30, 2026 (bonds and loans JPY 4,940.0 billion less cash JPY 461.0 billion); adjusted net debt to adjusted EBITDA 2.7x. Q1 FY2026 adjusted free cash flow JPY 68.6 billion. Profitable; no runway guidance applies. [Source](https://www.sec.gov/Archives/edgar/data/1395064/000139506426000327/exhibit991_073026.htm) Q1 FY2026 (April to June 2026) revenue JPY 1,219.9 billion, up 10.2% at actual rates and down 0.5% at constant exchange rates. [Source](https://www.takeda.com/newsroom/newsreleases/2026/takeda-reports-first-quarter-fy2026-results/) ## Risks on the record - A US jury awarded USD 884.9 million in single damages in the Amitiza antitrust case, much of it subject to trebling; Takeda booked a JPY 402.5 billion provision and is appealing. [Source](https://www.takeda.com/newsroom/newsreleases/2026/financial-results-update-amitiza-antitrust-litigation/) - Vyvanse loss of exclusivity: sales fell 17.0% at constant rates in Q1 FY2026, and Takhzyro fell 2.2% on US competition. [Source](https://www.sec.gov/Archives/edgar/data/1395064/000139506426000327/form6k_073026.htm) - FY2026 guidance calls for core revenue to decline at a low single-digit rate and core operating profit to fall 5% to 8% at constant rates. [Source](https://www.sec.gov/Archives/edgar/data/1395064/000139506426000327/form6k_073026.htm) ## Questions investors ask ### What is aibio.space's Investor Rank for Takeda Pharmaceutical Co.? 7 out of 10, our positive view. Three new drugs approved or under priority review, but Vyvanse generics, a guided profit decline, 2.7 times leverage and the Amitiza provision weigh on the position. This is opinion only, not a recommendation to buy, sell or hold, and it does not consider the share price or valuation. [Source](https://aibio.space/disclosures/#rank) ### Who is the CEO of Takeda? Julie Kim became Takeda's representative director, president and CEO on June 24, 2026, succeeding Christophe Weber, who retired after 12 years. [Source](https://www.takeda.com/newsroom/newsreleases/2026/julie-kim-appointed-president-ceo-takeda/) ### When does Takeda report Q2 FY2026 results? Takeda will host its earnings call for the second quarter of fiscal 2026 on October 29, 2026. It will also hold a Capital Markets Day on December 11, 2026. [Source](https://www.takeda.com/newsroom/newsreleases/2026/earnings-call-q2-fy2026/) ### What is Orzeyful approved for? The FDA approved Orzeyful (oveporexton) on August 5, 2026 for adults with narcolepsy type 1. It is an oral orexin receptor 2 agonist, and Takeda said on October 15 that the US launch is set for November following DEA scheduling. [Source](https://www.takeda.com/newsroom/newsreleases/2026/orzeyful-approved-narcolepsy/) ### When is the FDA decision on zasocitinib? The FDA accepted Takeda's application for zasocitinib in moderate-to-severe plaque psoriasis under priority review, with a PDUFA target date in the first quarter of calendar 2027. [Source](https://www.takeda.com/newsroom/newsreleases/2026/fda-priority-review-zasocitinib-psoriasis/) ### What happened in the Takeda Amitiza antitrust case? On May 18, 2026 a US jury awarded plaintiffs USD 884.9 million in single damages, with wholesaler and retailer awards subject to trebling. Takeda recorded a JPY 402.5 billion provision and said it will appeal. [Source](https://www.takeda.com/newsroom/newsreleases/2026/financial-results-update-amitiza-antitrust-litigation/) ### Is Takeda Pharmaceutical Co. a smaller reporting company? SEC records list Takeda Pharmaceutical Co. Ltd.'s filer category as: Large accelerated filer. Source ### Where is Takeda Pharmaceutical Co. headquartered? SEC records list its business address as 1-1, NIHONBASHI-HONCHO 2-CHOME, CHUO-KU, TOKYO, Japan, 103-8668. Source ### What did Takeda Pharmaceutical Co. last file with the SEC? Its most recent filing in our record is a 6-K filed 2026-09-14. All of its filings are on SEC EDGAR. [Source](https://www.sec.gov/Archives/edgar/data/1395064/000139506426000337/form6k_091426.htm) ### What industry is Takeda Pharmaceutical Co. in? Its SEC industry code (SIC 2834) is Pharmaceutical Preparations. Source ## Legal and investor matters Checked against Takeda Pharmaceutical Co. filings and press releases. Allegations are allegations; nothing here is a finding of fault. Reviewed Oct 25, 2026. Note 31 of the 20-F filed 2026-06-17 states that Takeda is involved in various legal and administrative proceedings and describes the most significant, including several antitrust class actions by drug purchasers (Actos, Amitiza, Colcrys and Dexilant). The Amitiza case went to a jury verdict on 2026-05-18. [Source](https://www.sec.gov/Archives/edgar/data/1395064/000139506426000177/tak-20260331.htm) 1. 2026-06-17 Regulatory Takeda resolves DOJ Trintellix investigation for USD 13.67 million Takeda received a civil investigative demand from the Department of Justice on February 19, 2020, seeking information as part of an investigation of possible off-label promotion and Anti-Kickback Statute violations in connection with Trintellix. In May 2026 Takeda finalized an agreement with the DOJ to resolve the matter for USD 13.67 million, according to its 20-F filed June 17, 2026. Takeda says it has not admitted and expressly denies wrongdoing, and that the settlement has no material impact on its consolidated statements of profit or loss. Status: settled [Takeda Form 20-F, 2026-06-17](https://www.sec.gov/Archives/edgar/data/1395064/000139506426000177/tak-20260331.htm) 2. 2026-06-17 Litigation Third parties file patent revocation actions against Takeda's Entyvio patents The 20-F filed June 17, 2026 reports that from February to April 2026 third parties brought patent revocation proceedings in the United Kingdom and the Netherlands against certain Takeda patents relating to Entyvio. The patents cover aspects of intravenous and subcutaneous dosing and some formulations. Takeda says the proceedings are ongoing and at an early stage. United Kingdom and Netherlands courts · Status: pending [Takeda Form 20-F, 2026-06-17](https://www.sec.gov/Archives/edgar/data/1395064/000139506426000177/tak-20260331.htm) 3. 2026-06-17 Litigation Dexilant antitrust suits by pharmacies and purchaser classes against Takeda In March 2025, four retail pharmacies sued Takeda and Twi Pharmaceuticals in the U.S. District Court for the Northern District of California, alleging that their April 2015 settlement of Dexilant patent litigation violated antitrust law. Complaints on behalf of classes of direct and indirect purchasers and further pharmacies followed, asserting substantially the same allegations. Takeda lists the matter in the 20-F filed June 17, 2026. U.S. District Court for the Northern District of California · Status: pending [Takeda Form 20-F, 2026-06-17](https://www.sec.gov/Archives/edgar/data/1395064/000139506426000177/tak-20260331.htm) 4. 2026-06-17 Litigation Takeda lists pending Actos and Colcrys antitrust class actions The 20-F filed June 17, 2026 describes two Actos antitrust class actions against Takeda in the Southern District of New York, filed in December 2013 by a putative class of patients and in April 2015 by a putative class of wholesalers. Plaintiffs allege Takeda improperly characterized certain Actos patents in the FDA Orange Book, delaying generic entry. It also describes a Colcrys antitrust class action filed in the Southern District of New York in November 2023 by plaintiffs seeking to represent a putative class of end payors, challenging patent settlements. Takeda reached an agreement in September 2023, fully executed in December 2023, to resolve an earlier Colcrys wholesaler class action for an amount it describes as immaterial. U.S. District Court for the Southern District of New York · Status: pending [Takeda Form 20-F, 2026-06-17](https://www.sec.gov/Archives/edgar/data/1395064/000139506426000177/tak-20260331.htm) 5. 2026-05-18 Litigation Jury awards USD 884.9 million single damages against Takeda in Amitiza case On May 18, 2026, a jury in the U.S. District Court for the District of Massachusetts awarded plaintiffs USD 884,943,990 in single damages in the Amitiza antitrust case. The case consolidates actions by a putative class of wholesalers, a putative class of third-party payors and individual retailers, who allege that Takeda's 2014 patent settlement with Par Pharmaceutical was anticompetitive. Damages awarded to the wholesaler class and retailers are to be automatically trebled upon entry of judgment; those for the third-party payor class remain subject to further proceedings. Takeda reported provisions of JPY 403,510 million related to the matter at March 31, 2026 and says it will pursue post-trial motions and an appeal. The verdict is not enforceable until the court enters judgment. U.S. District Court for the District of Massachusetts · Status: pending [Takeda Form 6-K, 2026-05-19](https://www.sec.gov/Archives/edgar/data/1395064/000139506426000149/form6k_051926.htm) ## Pipeline | Program | Indication | Stage | |---|---|---| | Zasocitinib (TAK-279) | Moderate-to-severe plaque psoriasis | NDA under FDA priority review, PDUFA date in Q1 calendar 2027; EMA application accepted [Source](https://www.takeda.com/newsroom/newsreleases/2026/fda-priority-review-zasocitinib-psoriasis/) | | Orzeyful (oveporexton) | Narcolepsy type 1 | Approved in US (Aug 5, 2026), China and Japan; launched in Japan and China on Oct 15; US launch set for November following DEA scheduling [Source](https://www.takeda.com/newsroom/newsreleases/2026/oveporexton-launches-simultaneously-in-japan-and-china/) | | Mimrylo (rusfertide) | Erythrocytosis in polycythemia vera | FDA approved Aug 28, 2026 [Source](https://www.takeda.com/newsroom/newsreleases/2026/fda-approval-mimrylo/) | | Arcotatug tavatecan (TAK-921) | Previously treated advanced gastric or GEJ adenocarcinoma | Phase 3 G-HOPE-001; late-breaking data at ESMO 2026 [Source](https://www.takeda.com/newsroom/newsreleases/2026/esmo-pipeline-progress/) | | TAK-928 | Squamous non-small cell lung cancer after chemotherapy and immunotherapy | Global phase 3 MarsLight-11 enrolling [Source](https://www.takeda.com/newsroom/newsreleases/2026/esmo-pipeline-progress/) | ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open TSE:4502 on TradingView](https://www.tradingview.com/symbols/TSE-4502/). ## SEC filings and registration - **SEC name**: Takeda Pharmaceutical Co Ltd - **CIK**: 1395064 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: TAK (NYSE), TKPHF (OTC) - **Filer category**: Large accelerated filer - **Business address**: 1-1, NIHONBASHI-HONCHO 2-CHOME, CHUO-KU, TOKYO, Japan, 103-8668 - **Phone**: 81332782111 - **Shares outstanding**: 1,557,765,596 as of 2020-03-31 (20-F filed 2020-06-24) ### Recent filings (8-K and 6-K are the company's own announcements) - [6-K](https://www.sec.gov/Archives/edgar/data/1395064/000139506426000337/form6k_091426.htm) filed 2026-09-14 - [6-K](https://www.sec.gov/Archives/edgar/data/1395064/000139506426000331/form6k_082826.htm) filed 2026-08-31 - [6-K](https://www.sec.gov/Archives/edgar/data/1395064/000139506426000329/form6k_080526.htm) filed 2026-08-06 - [6-K](https://www.sec.gov/Archives/edgar/data/1395064/000139506426000327/form6k_073026.htm) filed 2026-07-30 - [6-K](https://www.sec.gov/Archives/edgar/data/1395064/000139506426000280/form6k_070926.htm) filed 2026-07-09 - [6-K](https://www.sec.gov/Archives/edgar/data/1395064/000139506426000278/form6k_070826.htm) filed 2026-07-08 - [6-K](https://www.sec.gov/Archives/edgar/data/1395064/000139506426000189/form6k_062926.htm) filed 2026-06-29 - [6-K](https://www.sec.gov/Archives/edgar/data/1395064/000139506426000187/form6k_062626.htm) filed 2026-06-26 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001395064), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/takeda-pharmaceutical/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Takeda Pharmaceutical Co. (4502) stock news and catalysts", 2026-10-31, https://aibio.space/companies/takeda-pharmaceutical/